Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and fund lead clinical work on CBX‑250, a T‑cell engager targeting relapsed or refractory myeloid malignancies. CEO Briggs Morrison said the round will support completion of the lead Phase I study and broaden the pipeline—Crossbow has now also nominated a second candidate, CBX‑663. The company’s T‑Bolt approach generates antibodies that mimic T‑cell receptor recognition of HLA‑presented peptides, enabling targeting of intracellular cancer antigens not accessible to conventional antibodies.